Statement: Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial.
Primary_evidence: Inclusion Criteria:   Ability to understand and the willingness to sign a written informed consent document.   Signed written informed consent.   Women undergoing sentinel lymph node biopsy.   Women with breast cancer with known or suspected lymph node involvement.   Women undergoing sentinel node identification and completion axillary lymph node dissection.   Women of 18 years of age or older.   Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2.   Complete Blood Count (CBC) and basic Metabolic Panel within 6 months Exclusion Criteria:   History of liver or kidney failure will not be eligible.   Allergies to iodine containing products will not be eligible.   Women who are pregnant will not be eligible.   Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
Secondary_evidence: Inclusion Criteria:   The participant is Japanese   The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1   The participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is now metastatic or locally-recurrent and inoperable with curative intent   The participant has measurable and/or non-measurable disease   The participants' primary and/or metastatic tumor is Human Epidermal Growth Factor Receptor 2 (HER2) negative   The participant received neo adjuvant or adjuvant taxane therapy  6 months prior to the study   The participant received neo adjuvant or adjuvant biologic therapy  6 weeks prior to the study   The participant completed all prior radiotherapy  3 weeks prior to the study registration date   The participant received prior hormonal therapy for breast cancer in the neo adjuvant, adjuvant,and/or the metastatic setting  2 weeks prior to the study registration date   The participant's left ventricular ejection fraction (LVEF) is within normal ranges   The participant has adequate hematologic, hepatic, and coagulation function.   Eligible participants of reproductive potential agree to use adequate contraceptive methods (hormonal or barrier methods) during the study period and for 12 weeks after the last dose of study medication Exclusion Criteria:   The participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. Participants with previous treatment of malignancy is eligible, provided that she has been disease free for >3 years   The participant has a known sensitivity to docetaxel   The participant has a known sensitivity to agents of similar biologic composition as ramucirumab   The participant has a history of chronic diarrheal disease within 6 months prior to the study registration date   The participant has received irradiation to a major bone marrow area within 30 days prior to the study registration date   The participant has received any experimental agents within 4 weeks prior to the study registration date   The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders   The participant has Grade 3-4 bleeding within 3 months prior to the study registration date   The participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy   The participant has uncontrolled hypertension, symptomatic congestive heart failure, psychiatric illness, or any other serious uncontrolled medical disorders   The participant has brain metastases   The participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome related illness   The participant is pregnant or lactating   The participant has not fully recovered from effects of prior chemotherapy   The participant has undergone major surgery within 28 days prior to the study registration date